R&D channel feed – Endpoints News

R&D channel feed

Calliditas claims mid-stage win for rare liver disease drug

10 months ago

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

10 months ago

FDA advisors call for better studies of immunotherapy around lung cancer surgery, but give AstraZeneca a pass

10 months ago

Sanofi shelves four assets, including mid-stage dwarfism candidate

10 months ago

AbbVie expects $8.7B Cerevel buy to close ‘as early as next week,’ new CEO says

10 months ago

Roche cuts two more TIGIT trials, plans accelerated timeline for obesity drugs

10 months ago

Argenx to retest Vyvgart in autoimmune platelet disease after failure last year

10 months ago

Viking to push obesity drug to Phase 3 in bid to reach market faster

10 months ago

Pfizer touts Phase 3 gene therapy data in hemophilia A, but now it needs to prove it can win the market

10 months ago

Sage's essential tremor drug fails in another blow to pipeline, Biogen partnership

10 months ago

Exclusive: RA Capital invests $35M in UK cancer biotech CellCentric

10 months ago

AstraZeneca signs preclinical EGFR drug deal with antibody biotech

10 months ago

What's changed about rare disease medicine

10 months ago

Updated: Merck, without sharing details, says RSV antibody successfully protected infants

10 months ago

Cellectar to seek approval for radioactive iodine-based therapy in rare blood cancer

10 months ago

Flagship launches AI-powered biologics biotech with $50M backing

10 months ago

GSK says Dovato was as effective as Biktarvy in head-to-head HIV trial — but patients gained less weight

10 months ago

Chinese biotech boasts competitive Phase 2b weight loss data for GLP-1 drug

10 months ago

Ionis flashes new Angelman syndrome data, will pursue Phase 3 trial next year

10 months ago

Roivant recently sold one spinout for billions. Is Priovant next?

10 months ago

George Church spinout raises $60M for protein therapies from genomically recoded organisms

10 months ago

Q&A: How argenx’s CEO plans to create a sequel to Vyvgart (and beat the IRA)

10 months ago

Aveo Oncology’s Fotivda combo fails in Phase 3 kidney cancer test

10 months ago

Novartis CEO: Trying to crack obesity market with another first-gen agent is 'not a prudent approach'

10 months ago

First page Previous page 35 36 373839 40 41 Next page Last page